Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma

On November 17, 2026 Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, reported updated clinical data from the Phase 1/2 expansion study evaluating ozekibart (INBRX-109), an investigational tetravalent death receptor 5 (DR5) agonist, in combination with irinotecan and temozolomide (IRI/TMZ) in patients with relapsed or refractory Ewing sarcoma. The data will be presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The updated clinical data to be presented at CTOS underscore the deep activity and expanding reach of ozekibart in aggressive, difficult-to-treat bone and soft tissue sarcomas," said Mark Lappe, Chief Executive Officer of Inhibrx. "In relapsed or refractory Ewing sarcoma, achieving a 62.7% overall response rate, an 86.3% disease control rate, and clinically meaningful durability is particularly compelling in a population that has exhausted effective options. Based on these results, we intend to rapidly advance our plans with the goal of allowing patients access as soon as possible."

Ewing Sarcoma

As of the September 18, 2026, data cutoff, 60 patients (including 9 adolescent patients) were enrolled and treated with ozekibart plus IRI/TMZ, with 22 patients remaining on active treatment. Among the 51 response-evaluable patients, the combination demonstrated an overall response rate (ORR) of 62.7%, comprising 2 complete responses (CRs) and 30 partial responses (PRs). A total of 84.3% of response-evaluable patients (43/51) experienced measurable reduction in tumor size from baseline. An additional 12 patients achieved stable disease (SD), resulting in a Disease Control Rate (DCR) of 86.3%.

The median progression free survival (mPFS) was 6.0 months (95% CI: 4.6–7.4). Durable clinical benefit exceeding 6 months was observed in 18 patients (1 CR, 1 SD, 16 PRs), including 1 patient maintaining an ongoing PR for more than 2 years. At the cutoff date, 14 response-evaluable patients remained progression-free, including 2 patients with a PFS duration exceeding 12 months.

These data represent a meaningful improvement over historical benchmarks, such as irinotecan and temozolomide alone in relapsed or refractory Ewing sarcoma, which typically yield an ORR of approximately 15% to 30% and a mPFS of roughly 3 to 4 months.

The combination continued to demonstrate an acceptable and manageable safety profile consistent with the known cytotoxic toxicities of IRI/TMZ and DR5 agonism, with no evidence of unexpected cumulative hepatotoxicity.

The FDA accepted for filing our biologics license application for the potential approval of ozekibart in conventional chondrosarcoma. With approximately 300 new cases of Ewing sarcoma diagnosed each year in the U.S. and an estimated 2,500 individuals in the U.S. currently living with Ewing sarcoma, the need for novel therapeutic options in this underserved community is profound, and we look forward to discussing these results with the FDA.

Presentation Materials

Ewing Sarcoma Poster Details:

Title: Phase 1/2 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined with Irinotecan (I) and Temozolomide (T) in Adolescents and Adults with Ewing Sarcoma (EWS)
Session: Poster Presentation Session
Abstract Number: 2465416
Presenter: Varun Monga, M.D.
Date: Thursday, November 19, 2026
The poster materials will be made available in the "Events & Presentations" section of the Inhibrx Biosciences investor portal at inhibrxbiosciences.investorroom.com.

About ozekibart (INBRX-109)

Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. Ozekibart is engineered to optimize tumor-biased receptor clustering and activation without requiring secondary crosslinking, avoiding the severe hepatotoxicity observed with first-generation DR5-targeting agents.

(Press release, Inhibrx, NOV 17, 2026, View Source [SID1234674890])